Spago Nanomedical AB (SPAGO) Stock Price & Analysis

1 Followers

SPAGO Stock Chart & Stats

kr 0.03-kr 0.00(-2.94%)

At close: Nov 03 5:30 PM GMT+1

Day’s Range: SEK 0.03 - SEK 0.04
52-Week Range: SEK 0.03 - SEK 0.21
Previous Close: SEK 0.03
Volume: N/A
Average Volume (3M): 1.71M
Market Cap: SEK 27.46M
Enterprise Value: SEK 44.74M
Total Cash (Recent Filing): SEK 32.51M
Total Debt (Recent Filing): SEK 0
Price to Earnings (P/E): ―
Beta: 1.21
Next Earnings: Nov 05, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet

Zero debt reduces financial risk and avoids scheduled principal and interest obligations while Spago advances its development programs. This preserves financial flexibility relative to a leveraged biotech, although the benefit is partly offset by ongoing losses and the need to fund operations.

Losses Have Generally Narrowed

The reduction in annual losses indicates some improvement in cost control or operating efficiency compared with earlier periods. If sustained, this could extend the company’s funding runway and reduce future financing pressure, but profitability remains distant because revenue is still very small.

Proprietary Oncology Nanomedicine Focus

A focused platform in oncology nanomedicine gives Spago a clear strategic direction across cancer imaging and targeted treatment applications. Proprietary candidates may support differentiated development opportunities, though their long-term value depends on advancing from development into commercial use.

Bears Say

Minimal And Declining Revenue

Extremely low and declining revenue shows that Spago has not yet established meaningful commercial scale to support its operating base. This leaves financial performance highly dependent on development progress and external funding rather than recurring customer-driven cash generation over the coming periods.

Persistent Cash Burn

Persistent negative operating and free cash flow means the business is not self-funding and must continue financing its activities while revenue remains limited. Ongoing cash outflows can constrain development choices and create recurring funding needs even if the rate of burn improves.

Shrinking Equity Cushion

The substantial reduction in equity indicates that accumulated losses or capital structure changes have materially reduced the company’s financial cushion. A smaller equity base provides less capacity to absorb continued operating deficits and increases the importance of securing funding before resources become constrained.

SPAGO FAQ

What was Spago Nanomedical AB’s price range in the past 12 months?

Spago Nanomedical AB lowest stock price was kr 0.03 and its highest was kr 0.21 in the past 12 months.

What is Spago Nanomedical AB’s market cap?

Spago Nanomedical AB’s market cap is kr 27.46M.

When is Spago Nanomedical AB’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Spago Nanomedical AB’s earnings last quarter?

Spago Nanomedical AB released its earnings results on Aug 20, 2026. The company reported -kr 0.011 earnings per share for the quarter.

Is Spago Nanomedical AB overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Spago Nanomedical AB pay dividends?

Spago Nanomedical AB does not currently pay dividends.

What is Spago Nanomedical AB’s EPS estimate?

Spago Nanomedical AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Spago Nanomedical AB have?

Spago Nanomedical AB has 798,380,100 shares outstanding.

What happened to Spago Nanomedical AB’s price movement after its last earnings report?

Spago Nanomedical AB reported an EPS of -kr 0.011 in its last earnings report. Following the earnings report the stock price went up 3.448%.

Which hedge fund is a major shareholder of Spago Nanomedical AB?

Currently, no hedge funds are holding shares in SE:SPAGO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description